Next Article in Journal
KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer
Next Article in Special Issue
MTH1 as a Chemotherapeutic Target: The Elephant in the Room
Previous Article in Journal
HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance
Previous Article in Special Issue
DNA Repair Pathway Alterations in Bladder Cancer
Article Menu
Issue 5 (May) cover image

Export Article

Open AccessReview
Cancers 2017, 9(5), 41;

Targeting the ATR-CHK1 Axis in Cancer Therapy

Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne NE2 4HH, UK
Northern Gynaecological Oncology Centre, Queen Elizabeth Hospital, Gateshead NE9 6SX, UK
Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne NE7 7DN, UK
Authors to whom correspondence should be addressed.
Academic Editor: Eddy S. Yang
Received: 15 February 2017 / Revised: 23 April 2017 / Accepted: 25 April 2017 / Published: 27 April 2017
(This article belongs to the Special Issue DNA Repair Pathways in Cancer)
Full-Text   |   PDF [3036 KB, uploaded 27 April 2017]   |  


Targeting the DNA damage response (DDR) is a new therapeutic approach in cancer that shows great promise for tumour selectivity. Key components of the DDR are the ataxia telangiectasia mutated and Rad3 related (ATR) and checkpoint kinase 1 (CHK1) kinases. This review article describes the role of ATR and its major downstream target, CHK1, in the DDR and why cancer cells are particularly reliant on the ATR-CHK1 pathway, providing the rationale for targeting these kinases, and validation of this hypothesis by genetic manipulation. The recent development of specific inhibitors and preclinical data using these inhibitors not only as chemosensitisers and radiosensitisers but also as single agents to exploit specific pathologies of tumour cells is described. These potent and specific inhibitors have now entered clinical trial and early results are presented. View Full-Text
Keywords: ATR; CHK1; cell cycle; chemotherapy-sensitising-agents; DNA-damage; DNA-repair; protein-kinase-inhibitors; radiation-sensitising-agents ATR; CHK1; cell cycle; chemotherapy-sensitising-agents; DNA-damage; DNA-repair; protein-kinase-inhibitors; radiation-sensitising-agents

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Rundle, S.; Bradbury, A.; Drew, Y.; Curtin, N.J. Targeting the ATR-CHK1 Axis in Cancer Therapy. Cancers 2017, 9, 41.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top